Drug Profile


Alternative Names: CRTX 080; Lixar; VPA 985; WAY VPA 985

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Chiesi USA; Palladio Biosciences
  • Class Azepines; Benzamides; Small molecules
  • Mechanism of Action Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Polycystic kidney disease
  • No development reported Hyponatraemia

Most Recent Events

  • 04 Oct 2017 Phase-II clinical trials in Polycystic kidney disease in USA (PO), prior to October 2017
  • 04 Oct 2017 Lixivaptan receives Orphan Drug status for Polycystic kidney disease in USA
  • 23 May 2017 Lixivaptan licensed to Palladio Biosciences worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top